NCT02078830View on ClinicalTrials.gov

Prospective Randomised Study for Use of CHG Dressing at Entry Site of EVD's to Reduce EVD-associated Infections

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2017

Conditions
Wound Contamination
Interventions
DEVICE

3M™ Tegaderm™ CHG I.V. Securement Dressing

Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.

DEVICE

Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing

Placebo Dressing with the same shape like the CHG-Dressing without CHG.

Trial Locations (1)

4031

Universitätsspital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT02078830 - Prospective Randomised Study for Use of CHG Dressing at Entry Site of EVD's to Reduce EVD-associated Infections | Biotech Hunter | Biotech Hunter